JP2018526416A5 - - Google Patents

Download PDF

Info

Publication number
JP2018526416A5
JP2018526416A5 JP2018512944A JP2018512944A JP2018526416A5 JP 2018526416 A5 JP2018526416 A5 JP 2018526416A5 JP 2018512944 A JP2018512944 A JP 2018512944A JP 2018512944 A JP2018512944 A JP 2018512944A JP 2018526416 A5 JP2018526416 A5 JP 2018526416A5
Authority
JP
Japan
Prior art keywords
compound according
hydrogen
alkyl
aryl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018512944A
Other languages
English (en)
Japanese (ja)
Other versions
JP6966425B2 (ja
JP2018526416A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050685 external-priority patent/WO2017044567A1/en
Publication of JP2018526416A publication Critical patent/JP2018526416A/ja
Publication of JP2018526416A5 publication Critical patent/JP2018526416A5/ja
Application granted granted Critical
Publication of JP6966425B2 publication Critical patent/JP6966425B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018512944A 2015-09-09 2016-09-08 抗がん剤としての複素環式の限定された三環系スルホンアミド Expired - Fee Related JP6966425B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216168P 2015-09-09 2015-09-09
US62/216,168 2015-09-09
PCT/US2016/050685 WO2017044567A1 (en) 2015-09-09 2016-09-08 Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents

Publications (3)

Publication Number Publication Date
JP2018526416A JP2018526416A (ja) 2018-09-13
JP2018526416A5 true JP2018526416A5 (enExample) 2019-11-07
JP6966425B2 JP6966425B2 (ja) 2021-11-17

Family

ID=56940436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018512944A Expired - Fee Related JP6966425B2 (ja) 2015-09-09 2016-09-08 抗がん剤としての複素環式の限定された三環系スルホンアミド

Country Status (6)

Country Link
US (1) US10221158B2 (enExample)
EP (1) EP3347350A1 (enExample)
JP (1) JP6966425B2 (enExample)
CN (1) CN108349943A (enExample)
CA (1) CA2997769A1 (enExample)
WO (1) WO2017044567A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138500A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
CN106458916A (zh) 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
CN108349961B (zh) 2015-09-09 2022-02-18 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂
WO2021150695A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai Constrained n-substituted tetrahydrobenzoazepine sulfonamides as anticancer and neuroprotective agents
US20230020161A1 (en) * 2020-02-28 2023-01-19 Rappta Therapeutics Oy Tricyclic Modulators of PP2A
EP4121031A4 (en) * 2020-03-20 2024-03-27 Atux Iskay LLC 3-DIARYLMETHYLENE AND THEIR USE
CN114272378B (zh) * 2020-09-27 2023-06-23 四川大学华西医院 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途
AU2022216880A1 (en) * 2021-02-08 2023-08-10 Rappta Therapeutics Oy Substituted cyclic modulators of protein phosphatase 2a (pp2a) and methods using same
US20240368105A1 (en) 2021-08-18 2024-11-07 Atux Iskay Llc 2-diarylmethyl-4-aminotetrahydropyran derivatives and related compounds as anticancer, antiinflammatory, antifibrotic and neuroprotective agents
IL318597A (en) * 2022-08-04 2025-03-01 Rappta Therapeutics Oy Aromatic compounds for use as modulators of protein phosphatase 2A (PP2A)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634766A (en) 1983-10-31 1987-01-06 Merck Frosst Canada, Inc. 1,4-diaza-phenothiazines
GB8510680D0 (en) 1985-04-26 1985-06-05 Smith Kline French Lab Pyridine derivatives
US4882351A (en) 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
DE69431470T2 (de) 1993-07-26 2003-08-14 Eisai Co., Ltd. Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring
WO1997030038A1 (en) 1996-02-15 1997-08-21 Mitsubishi Chemical Corporation Diarylsultam derivatives
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
AU2641899A (en) 1998-02-27 1999-09-15 Eisai Co. Ltd. Heterocycle-fused benzothiazine derivatives
AR031612A1 (es) 2000-09-20 2003-09-24 Schering Corp Imidazoles sustituidos, composiciones farmaceuticas, metodo para su preparacion y el uso de los mismos para preparar un medicamento como agonistas o antagonistas h1 y h3 de histamina
EP1481673A4 (en) 2002-02-05 2008-09-24 Ajinomoto Kk MEDICAL COMPOSITIONS WITH GABAPENTIN OR PREGABALINE AND N-TYPE CALCIUM CHANNEL ANTAGONIST
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
CA2587664A1 (en) 2004-12-21 2006-06-29 Devgen N.V. Compounds with kv4 ion channel activity
IT1362675B (it) 2005-03-15 2009-06-25 Menarini Internat Operations Luxembourg Sa N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
ES2477868T3 (es) 2005-04-22 2014-07-18 Alantos Pharmaceuticals Holding, Inc. Inhibidores de dipeptidil peptidasa-IV
GB0508992D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2008121859A1 (en) 2007-03-30 2008-10-09 Xenon Pharmaceuticals Inc. Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions
CN103889981B (zh) 2011-08-16 2016-11-09 西奈山伊坎医学院 作为抗癌剂的三环化合物
WO2014031986A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102942562B (zh) 2012-12-05 2014-10-01 天津市斯芬克司药物研发有限公司 一种苯并咪唑衍生物及其制备方法和应用
CA2901493A1 (en) * 2013-02-19 2014-08-28 Icahn School Of Medicine At Mount Sinai Tricyclic heterocycles as anticancer agents
WO2015138500A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
CN106458916A (zh) 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
EP3331867A1 (en) 2015-08-06 2018-06-13 Icahn School of Medicine at Mount Sinai Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols
WO2017044572A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Ring constrained diarylamino sulfonamides as anti-cancer agents
WO2017044571A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
WO2017044575A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents
CN108349961B (zh) 2015-09-09 2022-02-18 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂

Similar Documents

Publication Publication Date Title
JP2018526416A5 (enExample)
JP2018526419A5 (enExample)
AU2016216963B2 (en) Condensed heterocyclic compounds and pesticides
AU2015355839B2 (en) Heterocyclic derivatives and use thereof
IL278297B2 (en) Substituted heterocyclic inhibitors of ptpn11
JP2016525075A5 (enExample)
CN108276352B (zh) 一种具有杀线虫活性的含氮杂环化合物及其制法和用途
WO2014062667A1 (en) Phenyl linked quinolinyl modulators of ror-gamma-t
JP2019513778A5 (enExample)
JP2014525420A5 (enExample)
JP2015143283A5 (enExample)
JP2012522763A5 (enExample)
JP2014524441A5 (enExample)
IL229007A (en) Parasiticidal dihydroisoxazole compounds
JP2014506599A5 (enExample)
JP2017508782A5 (enExample)
JP2018525375A5 (enExample)
MX2009010790A (es) Derivados de heteroarilo biciclico fusionados.
RU2016142309A (ru) Пестицидно активные гетероциклические производные с серосодержащими заместителями
PE20190806A1 (es) Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
HRP20220472T1 (hr) Novi derivati heteroarilamida kao selektivni inhibitori histonskih deacetilaza 1 i 2 (hdac1-2)
JP2016540803A5 (enExample)
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
JP2014510147A5 (enExample)
JP2006523698A5 (enExample)